Trial Profile
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pralatrexate (Primary)
- Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 27 Dec 2023 to 29 Jun 2024.
- 01 Feb 2024 Planned primary completion date changed from 27 Dec 2023 to 29 Jun 2024.
- 14 Aug 2023 Status changed from recruiting to active, no longer recruiting.